Microbial drug resistance : MDR : mechanisms, epidemiology, and disease
-
Microb. Drug Resist. · Dec 2012
Multicenter StudyClinical experience of tigecycline treatment in infections caused by extensively drug-resistant Acinetobacter spp.
Tigecycline has broad spectrum antimicrobial activity and is approved for complicated intra-abdominal infections, complicated skin and soft tissue infections, and community-acquired pneumonia. There are few data on clinical experience of tigecycline in hospital-acquired pneumonia (HAP) and Acinetobacter spp. infection. ⋯ Tigecycline can be considered as an alternative therapy in patients with HAP or infections caused by Acinetobacter spp., especially extensively drug-resistant A. baumannii.